CARDIOVASCULAR SYSTEMS receives two new qualifications and slightly improves to Neutral
The independent financial analyst theScreener just changed two ratings for the qualification of CARDIOVASCULAR SYSTEMS (US), active in the Medical Equipment industry. Its market behaviour has improved and can now be considered as moderately risky; its fundamental valuation receives an improved star rating and now shows 2 out of 4 stars. theScreener considers that these elements slightly improve the general evaluation, which passes therefore to Neutral. As of the analysis date April 1, 2022, the closing price was USD 23.34 and its expected value was estimated at USD 20.16.Cardiovascular Systems is a medical technology company. The company has developed an orbital atherectomy systems (OAS) for both peripheral and coronary commercial applications. The primary base of the company's business is catheter-based platforms capable of treating a range of vessel sizes and plaque types, including calcified plaque. The company's products include its coronary arterial disease (CAD) product, the Diamondback 360 Coronary OAS, which is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.